Co-Diagnostics
CODX
51 hedge funds and large institutions have $8.06M invested in Co-Diagnostics in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 14 increasing their positions, 15 reducing their positions, and 14 closing their positions.
397% more call options, than puts
Call options by funds: $308K | Put options by funds: $62K
0.05% less ownership
Funds ownership: 0.63% → 0.58% (-0.05%)
7% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 15
15% less funds holding
Funds holding: 60 → 51 (-9)
46% less capital invested
Capital invested by funds: $14.8M → $8.06M (-$6.75M)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$412K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$132K |
| 3 |
KAS
Kestra Advisory Services
Austin,
Texas
|
+$92.3K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$85.2K |
| 5 |
Squarepoint
New York
|
+$28.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
-$313K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$255K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$247K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$211K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$190K |
CODX Hedge Fund Activity: Q1 2023 in Review
51 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q1 2023, worth a combined $8.06M — down 46% from $14.8M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CODX and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 14 added.
The largest buyer was Morgan Stanley, adding an estimated $412K. The largest seller was Easterly Investment Partners, exiting entirely with an estimated $313K sold.
- 51 institutional investors held Co-Diagnostics (CODX) as of Q1 2023, down from 60 in Q4 2022.
- Funds reported $8.06M of Co-Diagnostics stock for Q1 2023, down 46% quarter-over-quarter.
- 6 funds opened new Co-Diagnostics positions in Q1 2023 and 14 closed out, a net change of -8 holders.
- The largest Co-Diagnostics buyer in Q1 2023 was Morgan Stanley, an estimated $412K added.
- The largest Co-Diagnostics seller in Q1 2023 was Easterly Investment Partners, an estimated $313K sold.
Based on aggregated 13F filings for Q1 2023.